The efficacy and safety of solifenacin vesicare therapy in patients with overactive bladder

Objective To evaluate the efficacy and safety of solifenacin vesicare therapy in patients with overactive bladder(OAB). Methods A double-blind randomized controlled clinical trial was conducted.A total of 76 patients with OAB were enrolled in the trial and assigned to treatment group and control group (n=38 each). Solifenacin vesicare was taken (5 mg qd after breakfast for 8 weeks) in treatment group,and tolterodine was taken (2 mg bid for 8 weeks) in control group.The courses of treatment were all eight weeks in two groups.The urination diary was recorded by oneself in all patients 1 week before and after treatment.The efficacy of solifenacin vesicare was assessed by comparing the improvement of mean frequency of urination and frequency of urgency episodes in 24 h in 1 week before and after medication according to urination diary and the changes of maximum flow rate(Qmax),volume of first desire to void(FDV)and maximum cystometric bladder capacity (MCBC) in two groups.The safety of solifenacin vesicare was appraised by comparing the incidence of drug adverse reactions in two groups. Results Compared with control group,the frequency of urination in 24 h,the frequency of urgency episodes in 24 h,FDV,MCBC and Qmax were all significantly improved in treatment group(all P0.05). Adverse reactions of drug in treatment group including xerostoma,visual field obscure and constipation were all lower than those in control group (all P005). Conclusions Solifenacin vesicare is a safer and more effective drug over tolterodine for the treatment of patients with OAB,and it could be served as a drug of first choice for treating OAB.